The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

Rahul A Parikh¹
Peng Wang²
Jan H Beumer³
Edward Chu¹
Leonard J Appleman¹
¹Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; ²Division of Medical Oncology, University of Kentucky College of Medicine, Markey Cancer Center, Lexington, KY, USA; ³University of Pittsburgh School of Pharmacy, Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Abstract: MET is located on chromosome 7q31 and is a proto-oncogene that encodes for hepatocyte growth factor (HGF) receptor, a member of the receptor tyrosine kinase (RTK) family. HGF, also known as scatter factor (SF), is the only known ligand for MET. MET is a master regulator of cell growth and division (mitogenesis), mobility (motogenesis), and differentiation (morphogenesis); it plays an important role in normal development and tissue regeneration. The HGF-MET axis is frequently dysregulated in cancer by MET gene amplification, translocation, and mutation, or by MET or HGF protein overexpression. MET dysregulation is associated with an increased propensity for metastatic disease and poor overall prognosis across multiple tumor types. Targeting the dysregulated HGF-MET pathway is an area of active research; a number of monoclonal antibodies to HGF and MET, as well as small molecule inhibitors of MET, are under development. This review summarizes the key biological features of the HGF-MET axis, its dysregulation in cancer, and the therapeutic agents targeting the HGF-MET axis, which are in development.

Keywords: MET inhibitor, HGF inhibitor, cancer

Hepatocyte growth factor (HGF)-MET pathway in normal development and tumorigenesis

Nearly 30 years ago, HGF was identified as a modulator of hepatocyte proliferation and regeneration by three independent groups of investigators.¹⁻³ HGF is a heterodimer with a larger α subunit and smaller β subunit with homology to tissue plasminogen.⁴ HGF is secreted by cells of mesenchymal origin and binds to the MET receptor on epithelial and endothelial cells. Scatter factor (SF), so named due to its ability to scatter mammary epithelial cells in culture, was characterized by complementary deoxyribonucleic acid (cDNA) cloning in 1990; SF was found to be identical to HGF, with indistinguishable ligand activity for the MET receptor.⁵ HGF is secreted as a precursor polypeptide bound to heparin proteoglycans in the extracellular matrix. The inactive HGF polypeptide is cleaved by a serine protease at sites of tissue injury and by tumor cells/matrix into active HGF. The only known ligand for the MET receptor is HGF, which upon binding to MET activates a downstream cascade, leading to cell survival, division, and motility.⁶

Activated MET kinase undergoes autophosphorylation on tyrosine residues (Tyr1349 and Tyr1356) in the docking domain, leading to recruitment and transduction of downstream effectors. Activated MET phosphorylates and binds to growth factor receptor-bound protein 2 (GRB2) and GRB2-associated binding protein 1 (GAB1), acting as a scaffold and promoting MET interactions with proteins involved in the
phosphoinositol 3-kinase (PI3K)-protein kinase B (Akt) pathway, the signal transducer and activator of transcription factor (STAT) pathway, the mitogen-activated protein kinase (MAPK) pathway, and the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) pathway. All of these pathways form an integral part of the MET-dependent cell growth, survival, and migration-signaling cascade. During embryogenesis, normal expression and function of HGF, MET, and GAB1 are essential for growth and development of hepatocytes, placental trophoblasts, and myoblasts. After birth, activation of the HGF-MET pathway appears to be involved in epithelial-mesenchymal transition, hepatic, renal, and other organ regeneration after injury, and wound healing. Figure 1 illustrates the HGF-MET signaling pathway.

In a subset of spontaneously transformed NIH-3T3 mouse fibroblasts, amplification and subsequent overexpression of the mouse MET gene was identified. This amplification was not seen in nontransformed NIH-3T3 cells and provided the initial proof of concept that the MET oncogene could act as a transforming factor. Subsequently, MET ribonucleic acid (RNA) and protein overexpression was observed in multiple epithelial and mesenchymal tumor cell lines, including breast, thyroid, liver, and kidney cancers. Transgenic mice with forced overexpression of HGF were noted to develop multiple epithelial and mesenchymal tumors. This diverse tumorigenesis was associated with MET phosphorylation and autocrine activation. Tumors arising in the tissues of these transgenic mice exhibited morphologic and developmental abnormalities, establishing the role of the HGF-MET pathway in tumorigenesis.

HGF and MET dysregulation in cancer

In human malignancies, the HGF-MET axis is dysregulated by a number of mechanisms, providing tumor cells with the ability to proliferate and disseminate. The MET gene is activated by point mutations in small-cell lung cancer (SCLC) and renal papillary carcinomas. MET protein is overexpressed in melanoma and musculoskeletal tumors.
Fusion of MET with translocated promoter region (TPR) in gastric carcinoma leads to MET overexpression.\textsuperscript{17–19} Aberrant HGF expression leading to autocrine activation of MET occurs in nearly half of acute myeloid leukemia cell lines, and depletion of HGF or MET leads to inhibition of growth and apoptosis.\textsuperscript{20} Transgenic mice overexpressing HGF have increased MET expression in tumor cells, providing them with a selective growth advantage; overexpression of HGF in tissues is associated with increased incidence of epithelial and mesenchymal tumors.\textsuperscript{13} In an elegant study, Lorenzato et al noted that activating somatic MET mutations were infrequent in primary tumors but commonly present at metastatic sites, suggesting that MET mutations are associated with progression rather than initiation of tumorigenesis.\textsuperscript{21} In colorectal tumors, MET amplification is associated with advanced stages and development of hepatic metastatic disease; gene amplification was observed in 2\% (3/177) of localized primary cancers, 9\% (6/70) of cancers with distant metastases ($P<0.02$), and 18\% (25/147) of liver metastases ($P<0.01$).\textsuperscript{22} Thus, alterations in MET and/or HGF are frequently observed in a wide range of cancers, and their presence appears to confer an increased propensity for a more aggressive clinical behavior manifested by invasion and metastasis.

Overexpression and upregulation of the HGF-MET pathway has been shown to be an important escape mechanism for tumor cells to develop resistance to inhibition of the epidermal growth factor receptor (EGFR), RAS-RAF-MEK, and Akt–mTOR (mammalian target of rapamycin) pathways. In a subset (22\%) of non-small-cell lung cancers (NSCLC) with activating mutations of the EGFR gene, MET amplification is associated with gefitinib resistance by promoting human epidermal growth factor receptor (HER)-3-mediated activation of PI3K.\textsuperscript{23} Overexpression of HGF followed by MET phosphorylation in NSCLCs with EGFR-activating mutations reactivates the PI3K-Akt signaling pathway and leads to gefitinib resistance.\textsuperscript{24} Similarly, resistance to RAS inhibitors is mediated by upregulation and secretion of HGF by the tumor microenvironment.\textsuperscript{25} MET activation was noted to mediate resistance to HER2 inhibition by lapatinib in HER2-amplified gastric cancer cells.\textsuperscript{26} In esophageal squamous cell carcinoma, secretion of HGF by fibroblasts is associated with a highly invasive phenotype and early disease progression.\textsuperscript{27} MET amplification is associated with a highly aggressive phenotype in a subset of gastro-esophageal adenocarcinomas.\textsuperscript{28} TP53 mutations or p53 deficiency is associated with MET dysregulation and promotes tumor cell mobility and invasion.\textsuperscript{29} Alterations in the HGF-MET axis can lead to development of resistance to inhibition of a number of different pathways; combining HGF/MET inhibition with targeted EGFR, MEK, or PI3K inhibitors would appear to represent a rational approach to treating these resistant tumors.

### Targeting the HGF-MET axis

Currently, a number of strategies targeting the HGF-MET pathway are in development. These approaches include the use of small molecule MET tyrosine kinase inhibitors (TKI), anti-HGF neutralizing antibodies, and anti-MET neutralizing antibodies. Each of these approaches will be reviewed below. The molecular sites of action for agents targeting the HGF-MET pathway are shown in Figure 2. Table 1 summarizes the target receptors, half-life, and characteristics of HGF-MET inhibitors. The development of a number of these agents has advanced to evaluation for efficacy in Phase II and Phase III clinical trials (Table 2). A timeline of significant pathways involving the HGF-MET axis and clinical development of agents targeting the HGF-MET pathway is shown in Figure 3.

#### Adenosine triphosphate (ATP)-competitive MET kinase inhibitors

Foretinib

Foretinib was developed as a small molecular inhibitor of MET and vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2/kinase insert domain receptor [KDR]) with additional activity against RON, KIT, fms-related tyrosine kinase (FLT)-1, FLT-3, platelet-derived growth factor receptor (PDGFR)-\(\alpha\), PDGFR-\(\beta\), fibroblast growth factor receptor (FGFR), EGFR, and tyrosine kinase with immunoglobulin-like and EGF-like domains (TIE)-2. Foretinib inhibits MET at a half maximal inhibitory concentration (IC\(_{50}\)) of 0.4 nmol/L; subsequently, it also inhibits HGF-mediated MET phosphorylation, migration, and invasion of MET-amplified human gastric cancer cell lines. In a mouse model with lung metastases, oral foretinib produced a significant dose-dependent reduction in both size and number of lung metastases, which led to its further development.\textsuperscript{30}

In the initial Phase I trial of foretinib in patients with metastatic or unresectable solid tumors, 40 patients were enrolled in eight dose cohorts. All patients received foretinib for 5 days orally every 14 days. The maximum tolerated dose (MTD) was 3.6 mg/kg and dose limiting toxicities included aspartate aminotransferase and lipase elevations. Responses were seen in two patients with papillary renal cell carcinoma and one patient with medullary thyroid carcinoma.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Summary of HGF-MET inhibitors</th>
</tr>
</thead>
</table>

[Note: Table 1 and Figure 2 are not included in this text.]

OncoTargets and Therapy 2014:7

submit your manuscript | www.dovepress.com
Dovepress

HGF-MET inhibitors in cancer

Dovepress
Table 1

<table>
<thead>
<tr>
<th>Agent</th>
<th>Company</th>
<th>Target</th>
<th>MTD</th>
<th>Half-life</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foretinib (XL-880)</td>
<td>GlaxoSmithKline</td>
<td>MET, RON, KIT, FLT-1, FLT-3, PDGFR-α, PDGFR-β, FGFR, EGFR, TIE-2</td>
<td>3.6 mg/kg</td>
<td>40 hours</td>
<td>31</td>
</tr>
<tr>
<td>Cabozantinib (XL-184)</td>
<td>Exelisix</td>
<td>MET, RET, TIE-2, VEGFR1-3, KIT, FLT-3, MET, ALK</td>
<td>175 mg daily</td>
<td>80–90 hours</td>
<td>58</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>Pfizer</td>
<td>MET, Cytotoxic activity</td>
<td>250 mg twice daily</td>
<td>42 hours</td>
<td></td>
</tr>
<tr>
<td>Tivantinib (ARQ-197)</td>
<td>ArQule</td>
<td>MET</td>
<td>360 mg twice per day dose (crystalline formulation)</td>
<td>3.2–6.1 hours</td>
<td>48–50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>300 mg twice per day dose (amorphous formulation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rilotumumab (AMG102)</td>
<td>Amgen</td>
<td>Human HGF</td>
<td>Not reached</td>
<td>14.5–22 days</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ficlatuzumab (AV-299)</td>
<td>Aveo</td>
<td>Human HGF</td>
<td>Not reached</td>
<td>15 days</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onartuzumab (MetMab)</td>
<td>Genentech</td>
<td>Human MET</td>
<td>Not reached</td>
<td>11 days</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: MTD, maximum tolerated dose; HGF, hepatocyte growth factor; FLT, fms-related tyrosine kinase; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast growth factor; EGFR, epidermal growth factor receptor; TIE-2, tyrosine kinase with immunoglobulin-like and EGF-like domains; VEGFR, vascular endothelial growth factor receptor; ALK, anaplastic lymphoma kinase.

In a Phase II study of foretinib in patients with papillary renal cell carcinoma, 74 patients were enrolled into two cohorts comparing daily to intermittent foretinib. A total of 37 patients in cohort A received 240 mg foretinib on days 1–5 every 14 days, while 37 patients in cohort B received...
Table 2 Results of key Phase II/III trials with HGF-MeT inhibitors

<table>
<thead>
<tr>
<th>Agent</th>
<th>Disease</th>
<th>Design</th>
<th>Results</th>
<th>Adverse events</th>
<th>Biomarkers</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foretinib</td>
<td>Papillary renal cell carcinoma</td>
<td>Phase II open-label</td>
<td>ORR, 13.5%, Median PFS, 9.3 months Median OS, not reached</td>
<td>Hypertension</td>
<td>Germline MET (gMET) mutation predictive of response, 50% ORR in gMET mutation positive patients versus 9% in gMET mutation-negative patients</td>
<td>31</td>
</tr>
<tr>
<td>Cabozantinib</td>
<td>Castrate resistant prostate cancer</td>
<td>Phase II randomized discontinuation trial</td>
<td>Median PFS (patients with SD at 12 weeks), 23.9 weeks versus 5.9 weeks in placebo arm. Improvement in bone scans 68% (CR 12%, PR 56%) 67% patients reported improvement in bone pain</td>
<td>Fatigue, Hypertension, Skin rash, Dehydration, Pulmonary embolism, Vomiting</td>
<td>None</td>
<td>RET and RAS mutation were predictive of response to cabozantinib</td>
</tr>
<tr>
<td>Medullary thyroid cancer</td>
<td>Phase III randomized double-blind placebo-controlled trial</td>
<td>Median PFS, 11.2 months for cabozantinib and 4.2 months for placebo (P&lt;0.0001) ORR of 28% versus 0% for the placebo arm</td>
<td>Diarrhea, Skin rash, Fatigue, Hypocalcemia, Hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crizotinib</td>
<td>ALK-rearranged NSCLC</td>
<td>Phase I open-label study</td>
<td>ORR, 57%, 6 month-PFS, 72%</td>
<td>Nausea, Vomiting, AST, ALT elevations</td>
<td>EML4-ALK translocation analyzed by FISH and RT-PCR</td>
<td>70</td>
</tr>
<tr>
<td>Tivantinib</td>
<td>Relapsed refractory germ cell tumors</td>
<td>Phase II single arm open-label</td>
<td>Median PFS 1 month 12-week-PFS 21% Median OS, 6 months Stable disease, 20% patients No objective CR or PR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MIT tumors</td>
<td>Phase II single arm open-label</td>
<td>Partial response, 2% SD, 60% Median PFS, 3.6 months (overall)</td>
<td></td>
<td></td>
<td>Baseline MET expression</td>
<td>51</td>
</tr>
<tr>
<td>Advanced hepatocellular carcinoma</td>
<td>Randomized double-blind placebo-controlled trial</td>
<td>Time to progression, 1.6 months versus placebo (1.4 months) HR, 0.64</td>
<td>Neutropenia</td>
<td>High expression of MET by IHC (≥2+ in ≥50% tumor cells)</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Rilotumab</td>
<td>Advanced metastatic renal cell carcinoma</td>
<td>Phase II open-label two doses of rilotumab 10 and 20 mg/kg</td>
<td>One confirmed PR SD, 3% One confirmed PR, 10 patients (16%) had SD ≥32 weeks Median PFS, 3.7 months with 10 mg/kg and 2 months with 20 mg/kg</td>
<td>Edema, Fatigue, Nausea, Anorexia</td>
<td>Baseline plasma HGF and soluble MET levels did not correlate as measure of efficacy</td>
<td>75</td>
</tr>
<tr>
<td>Recurrent Glioblastoma</td>
<td>Phase II study with two doses of rilotumab 10 and 20 mg/kg</td>
<td>ORR, 0% PFS, 4.1 weeks 10 mg/kg and 4.3 weeks 20 mg/kg OS, 6.5 weeks 10 mg/kg and 5.4 weeks 20 mg/kg</td>
<td>Fatigue, Headache, Peripheral edema</td>
<td></td>
<td>Plasma HGF increased 12-fold Soluble cMET increased 1.17-fold after treatment with rilotumab</td>
<td>76</td>
</tr>
</tbody>
</table>

(Continued)
Table 2 (Continued)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Disease</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rilotumumab</td>
<td>Castrate refractory prostate carcinoma</td>
<td>77</td>
</tr>
<tr>
<td>Ficlatuzumab</td>
<td>NSCLC</td>
<td>81</td>
</tr>
<tr>
<td>Quantrumab</td>
<td>Adenocarcinoma</td>
<td>86</td>
</tr>
</tbody>
</table>

74 patients were enrolled in a Phase II study of rilotumumab 15 mg/kg every 2 weeks or placebo, and Median OS 12.2 months versus 11.1 months for combined rilotumumab arms versus mitoxantrone alone arm respectively.

PHA-665752

PHA-665752 is an ATP-competitive small-molecule inhibitor of the MET kinase with additional activity against RON and VEGF2. In gastric carcinoma mouse-xenograft models, PHA-665752 inhibited MET phosphorylation and tumor growth.38 Treatment with PHA-665752 induced apoptosis in five of five gastric cancer cell lines with MET amplification but none of twelve cell lines without MET amplification.39 The addition of PHA-665752 to gefitinib, an EGFR TKI, reversed acquired resistance to gefitinib in lung cancer cell lines with MET amplification.34

BAY-853474

BAY-853474 is a selective, potent, oral small-molecule inhibitor of the MET kinase with additional activity against RON, FLT-1, FGFR, PDGFR, and other receptor

MK-2461

MK-2461 is an inhibitor of MET with additional activity against RON, FLT-1, FGFR, PDGFR, and other receptor
tyrosine kinases. In MET-amplified human GTL16 gastric cancer cell lines and a murine xenograft model of MET-dependent gastric cancer, oral MK-2461 inhibited MET signaling and cell growth. Genomic amplification of MET and constitutive activation of MET, FGFR2, or PDGFR2 were noted to be predictive of response to MK-2461.

AMG-458
AMG-458 is a potent inhibitor of the MET, VEGFR-2, and insulin-like growth factor 1 receptor signaling pathways. It significantly inhibited tumor growth in the NIH-3T3 cells transfected with TPR-MET, leading to constitutive activation of MET and U-87 MG human glioblastoma xenograft models. There is currently no clinical trial information available for AMG-458.

PF-04217903
PF-04217903 showed excellent in vitro activity against the MET-amplified human GTL16 gastric carcinoma and H1993 NSCLC cell lines. PF-04217903 partially inhibited proliferation in U-87 MG human glioblastoma cells and two colon cancer cell lines (SW620, HT29). PF-04217903 inhibited MET phosphorylation and tumor proliferation in both a GTL16 xenograft athymic mouse model with MET amplification and in a U-87 MG human glioblastoma xenograft model with an activated HGF-MET autocrine loop. A Phase I study of PF-04217903 in advanced cancer was terminated by Pfizer in early 2012.

Non-ATP-competitive MET kinase inhibitors
Tivantinib
Tivantinib (ARQ 197) is currently undergoing Phase II clinical development based upon preclinical cytototoxic activity and ATP non-competitive inhibition of MET with a minimal IC$_{50}$ of 0.1 µM by in vitro assay of recombinant kinase protein. Tivantinib binds to a hydrophobic cleft in the kinase domain, stabilizing the inactive conformation and inhibiting MET autophosphorylation. Tivantinib is orally
bioavailable, and it is metabolized by the liver cytochrome P450 (CYP) CYP2C19, and to a lesser extent by CYP3A4. Polymorphisms in CYP2C19 (CYP2C19*2 and CYP2C19*3) have been identified that are associated with decreased metabolism of tivantinib, resulting in significantly increased drug exposure. These polymorphisms are most commonly seen in Asians (35% allele frequency), but also occur in African-Americans (17%) and Caucasians (15%).

In vitro, tivantinib induced caspase-dependent apoptosis in MET-expressing human cancer cell lines, including the HT29 (colon adenocarcinoma), MKN-45 (gastric cancer), and MDA-MB-231 (breast cancer) cell lines; this small molecule demonstrated antitumor activity in a wide range of human cancer xenograft models.

The clinical pharmacology and safety profile of tivantinib have been investigated in several Phase I studies. The main dose-limiting toxicities have been leukopenia, neutropenia, thrombocytopenia, vomiting, and dehydration. At a dose of 400 mg daily, febrile neutropenia was observed in two subjects, one of whom also experienced grade 3 mucositis, palmar-plantar erythrodysesthesia, and hypokalemia. All toxicities were reversible upon discontinuation of tivantinib. Drug treatment was associated with a decrease in phosphorylated MET, significant decreases in total MET and phosphorylated focal adhesion kinase, and a significant increase in the level of apoptosis, as measured by a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The RP2D for tivantinib was established as 300 mg twice daily of the amorphous formulation, which is equivalent to 360 mg twice daily of the crystalline formulation.

In a Phase II study, 47 patients with advanced microphthalmia transcription factor (MITF)-associated tumors (MiT) were treated with 360 mg twice daily tivantinib. The study concluded that tivantinib was safe and tolerable in patients with MiT tumors, but antitumor activity was relatively modest, with a partial response in one clear cell sarcoma patient (2%) and stable disease in 28 patients (60%).

In a randomized, controlled Phase II study, the combination of tivantinib with erlotinib, an EGFR TKI, showed a trend towards improved progression-free survival (PFS) and overall survival (OS) compared with placebo with erlotinib; these results were found in a subset of patients with non-squamous histology, as well as in patients with wild-type EGFR. Interestingly, there was a significant benefit in PFS and OS in all 15 patients with mutated KRAS. Although the study did not meet its primary endpoint, evidence of activity was demonstrated, particularly among patients with KRAS mutations. MARQUEE was a randomized, double-blind, controlled study evaluating tivantinib versus placebo, in combination with erlotinib. Patients in the study had locally advanced or metastatic, non-squamous NSCLC, and had received prior treatment. However, the study was stopped early; at the planned interim analysis, there was no improvement in overall survival, the primary study endpoint. The combination of erlotinib with tivantinib demonstrated a statistically significant improvement in PFS, with no safety concerns in the intent-to-treat population.

Two recent preclinical studies have called into question the mechanism of tivantinib action. A series of experiments demonstrated that the cytotoxic effect of tivantinib on cell lines was independent of MET genetic status (wild-type, amplified, and/or kinase-deleted). Both studies observed that tivantinib caused G2 arrest, in sharp contrast to other MET inhibitors, which cause arrest at the G1 checkpoint. Both studies observed alterations in microtubule dynamics; in one study, tivantinib was noted to stabilize microtubules, while the other report observed that tivantinib destabilized microtubules. The potential implications for further clinical development of tivantinib as a MET inhibitor are discussed in a recent review.

**Multitargeted inhibitors of MET and other kinases**

**Cabozantinib**

Cabozantinib is an oral small molecule inhibitor of RET, MET, and VEGF-2, with additional activity against VEGF-1, VEGF-3, KIT, and FLT-3. Eighty-five patients with advanced solid malignancies, including an expansion cohort of 37 patients with medullary thyroid cancer (MTC), were enrolled in a Phase I dose-escalation study of oral cabozantinib. The MTD for cabozantinib was 175 mg, and dose-limiting toxicities included palmar-plantar erythrodysesthesia, mucositis, aspartate aminotransferase, alanine transaminase, and lipase elevations. Ten of 35 evaluable patients with MTC had a partial response; an additional 15 patients with MTC had stable disease for at least 6 months. Activating RET mutations were seen in 81% of patients with MTC and the presence of these mutations appeared to correlate with response to cabozantinib. In a Phase III EXAM study, 330 patients with locally advanced or metastatic MTC were assigned in a 2:1 ratio to receive cabozantinib 160 mg daily or placebo, respectively. Median progression-free survival, the primary endpoint, was 11.2 months for cabozantinib and 4.2 months for placebo ($P<0.0001$), with an ORR of
28% versus 0% for the placebo arm.\textsuperscript{39} Common grade 3 or greater adverse events associated with cabozantinib were diarrhea (15.9% versus 1.8%), palmar-plantar erythrodysesthesia (12.6% versus 0%), fatigue (9.3% versus 2.8%), hypocalcemia (9.3% versus 0%), and hypertension (7.9% versus 0%).\textsuperscript{39}

Based on these results, in late 2012 cabozantinib was approved by the US Food and Drug Administration (FDA) for the treatment of MTC. In the EXAM study, patients with \textit{RET} mutations had a significantly longer median PFS (60 weeks) compared to \textit{RET} mutation-negative patients (25 weeks). In the \textit{RET} mutation-negative subgroup, patients with \textit{RAS} mutations had a median PFS of 47 weeks, accounting for most of the benefit observed in this subgroup of patients.\textsuperscript{39} Thus, \textit{RET} and \textit{RAS} mutations in MTC are predictive of response to cabozantinib.

One hundred and seventy one men with castrate refractory prostate adenocarcinoma were enrolled in a Phase II randomized discontinuation trial with cabozantinib. The patients received 100 mg of cabozantinib for a 12-week run-in period, followed by randomization of patients with stable disease to cabozantinib or placebo. Due to the efficacy of cabozantinib, the randomization was halted early. The ORR at 12 weeks, a co-primary endpoint, was 5%, while 75% of patients had stable disease. In 31 patients with stable disease at 12 weeks who were randomly assigned to cabozantinib or placebo, the median progression-free survival was 23.9 months with cabozantinib and 5.9 months with placebo, resulting in a hazard ratio of 0.12. The most common dose limiting toxicities were fatigue, hypertension, and hand-foot syndrome.\textsuperscript{60}

Cabozantinib has a black-box warning for gastrointestinal perforations (3%), fistula formation (1%), and severe hemorrhage, which occurred in 3% of patients in the EXAM trial. Additional side effects include venous and arterial thrombosis, hypertension, and palmar-plantar erythrodysesthesia. Cabozantinib is highly protein-bound (99.7%) and has a long half-life of approximately 55 hours. Grapefruit juice and other grapefruit products can inhibit CYP enzymes and thus should be avoided with cabozantinib. A high-fat meal increased cabozantinib $C_{\text{max}}$ by 41% and area under curve by 57%; patients are thus recommended to not eat from 2 hours before until 1 hour after cabozantinib use. Concomitant ketoconazole use (a CYP inhibitor) in healthy subjects increased single-dose cabozantinib exposure by 38%, while rifampin use (a CYP inducer) reduced single-dose cabozantinib exposure by 77%. Thus coadministration of strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, atazanavir, ritonavir) or CYP3A4 inducers (phenytoin, dexamethasone, carbamazepine, rifampin, phenobarbital, St John’s Wort) should be avoided. Presently, there is limited data for cabozantinib use in hepatic impairment, and it should be avoided in patients with moderate to severe impairment. No dose adjustment is required for cabozantinib in patients with mild or moderate renal insufficiency.\textsuperscript{61} Cabozantinib is under investigation in multiple other tumor types and has shown preliminary activity in metastatic breast cancer,\textsuperscript{62} melanoma,\textsuperscript{63} hepatocellular carcinoma,\textsuperscript{64} renal cell carcinoma,\textsuperscript{65} NSCLC,\textsuperscript{66} ovarian cancer,\textsuperscript{67} and urothelial carcinoma.\textsuperscript{68}

### Crizotinib

Crizotinib is a small molecule inhibitor of the anaplastic lymphoma kinase (ALK) with additional activity against the MET, ROS, and RON receptors at clinically relevant doses. After evaluation of a panel of more than 120 kinases in biochemical and phosphorylation assays, crizotinib was identified to be nearly 20-fold more selective for both ALK and MET than other kinases.\textsuperscript{69} Based on the results of an open-label, two-part Phase I study in 82 patients, crizotinib was approved for use in ALK-rearranged advanced NSCLC. The overall response rate was 57% (46 partial and one complete response in 82 patients) with crizotinib use in this select group of patients with ALK rearrangements.\textsuperscript{70} Crizotinib was also noted to be active in patients with NSCLC with MET amplification but no ALK rearrangements and in patients with MET-amplified esophagogastric adenocarcinoma.\textsuperscript{28,71}

### Anti-HGF monoclonal antibodies

**Rilotumumab**

Rilotumumab (AMG 102) is a fully human anti-HGF neutralizing immunoglobulin G subclass 2 (IgG2) monoclonal antibody. In preclinical tests, a combination of rilotumumab and temozolomide, an oral cytotoxic alkylating agent, displayed growth inhibitory effects in a human glioblastoma cell line U-87 MG. In xenograft models, combining rilotumumab with temozolomide or docetaxel (a microtubule inhibitor, with cytotoxic activity) induced significant tumor growth inhibition compared to either agent alone.\textsuperscript{72} In Phase I studies, rilotumumab demonstrated linear kinetics with a mean half-life of 18 days. It was well-tolerated at the maximum planned dose of 20 mg/kg.\textsuperscript{73}

In the Phase I clinical trial with rilotumumab, 40 patients with refractory advanced solid malignancies were enrolled in six sequential dose-escalation cohorts and one dose expansion cohort. In the dose-escalation cohort, patients were administered doses of 0.5, 1, 3, 5, 10, or 20 mg/kg every 2 weeks...
until side-effects or disease progression were observed. Nine additional patients received rilotumumab at 20 mg/kg in the dose expansion cohort. Rilotumumab was well-tolerated with fatigue (13%), anorexia (8%), constipation (8%), and nausea (8%) being the most commonly observed toxicities. Sixteen of 23 evaluable patients (70%) had stable disease with PFS ranging from 7.9 to 40 weeks, with no actual responses. A Phase Ib study in patients with advanced solid malignancies combined rilotumumab with bevacizumab, a humanized VEGF-A monoclonal antibody (12 patients), or motesanib, a VEGF, PDGFR, and stem cell factor receptor inhibitor (2 patients). The patients were sequentially enrolled into four cohorts receiving 3, 10, or 20 mg/kg rilotumumab with 10 mg/kg of bevacizumab, or 3 mg/kg of rilotumumab intravenously every 2 weeks with 75 mg of oral daily motesanib. Enrollment into the motesanib arm was suspended early due to concern over cholecystitis caused by motesanib. Fatigue (72%), nausea (58%), constipation (42%), and peripheral edema (42%) were the most common treatment-related side effects. Eight of ten patients had reductions in the size of their tumors, with four patients demonstrating stable disease at week 24 after administration, and PFS ranged from 8–122 weeks.

A single arm, open-label, two-stage Phase II study enrolled 61 patients with advanced or metastatic renal cell carcinoma, with 40 patients receiving rilotumumab 10 mg/kg every 2 weeks, and 21 patients receiving the 20 mg/kg dose. The median PFS was 3.7 months at 10 mg/kg of rilotumumab and 2 months at the 20 mg/kg dose; one patient with a confirmed partial response remained on maintenance therapy for 2.5 years. Peripheral edema (46%), fatigue (38%), and nausea (28%) were the most common side effects associated with rilotumumab. In patients with relapsed or recurrent glioblastoma, 40 patients received rilotumumab 10 mg/kg every 2 weeks while 20 patients received rilotumumab at a dose of 20 mg/kg every 2 weeks as a part of a Phase II clinical trial. There were no objective responses based on central assessment, and median OS and PFS were 6.5 months and 4.1 weeks, respectively, in the 10 mg/kg dose cohort, and 5.4 months and 4.3 weeks in the 20 mg/kg dose cohort, respectively. Prior bevacizumab treatment had no effect on the study endpoints. Fatigue (38%), headache (33%), and peripheral edema (23%) were the most common side effects.

A double-blind Phase II randomized study was performed in patients with metastatic castrate-resistant prostate adenocarcinoma and who had progressed on prior taxane therapy. A total of 144 patients were assigned to receive rilotumumab 15 mg/kg every 2 weeks, 7.5 mg/kg every 2 weeks, or placebo in 1:1:1 manner in combination with mitoxantrone 12 mg/m² with prednisone. Median OS was 12.2 months in the combined rilotumumab arms versus 11.1 months in the placebo arm, and median PFS was 3 months compared to 2.9 months in the placebo arm. The combined rilotumumab arms demonstrated a higher number of patients with peripheral edema (24%) compared to the placebo arm (8%). A Phase III trial (RILOMET-1, NCT01697072) of epirubicin, cisplatin, and capecitabine (ECX) combined with rilotumumab or placebo for untreated, advanced, MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma is currently ongoing.

**Ficlatuzumab**

Ficlatuzumab (AV-299) is a humanized monoclonal anti-HGF IgG1 antibody that binds to HGF, thereby inhibiting the HGF-MET interaction. In a Phase I study, 24 patients with solid malignancies were treated with single agent ficlatuzumab at 2, 5, 10, and 20 mg/kg, respectively, every 2 weeks, while 13 patients received the combination of ficlatuzumab 20 mg/kg every 2 weeks and erlotinib 150 mg daily. Grade 3 mucositis was seen in one patient on single-agent ficlatuzumab. Rash and diarrhea were common adverse events seen with combination therapy. The half-life of single-agent ficlatuzumab was observed to be approximately 15 days, and no MTD was determined. Ficlatuzumab therapy was associated with elevated serum HGF levels but no changes in serum soluble-MET levels.

A Phase Ib study combined gefitinib 250 mg daily with two dose levels of ficlatuzumab (10 and 20 mg/kg every 2 weeks) in Asian patients with unresectable NSCLC. Of the 15 patients enrolled in the study, none had dose-limiting toxicities, while common adverse events included cough, rash, poor appetite, and diarrhea. At the 20 mg/kg dose, five patients had a partial response and four had stable disease at 12 weeks of treatment. A multicenter, randomized open-label Phase II study evaluated a combination of ficlatuzumab with gefitinib versus gefitinib alone in 188 patients of Asian ethnicity with stage IIIB or stage IV NSCLC. The overall response rate was comparable for the combination (43%) and the gefitinib alone arms (40%). Median PFS was 5.6 months in the ficlatuzumab plus gefitinib arm compared to 4.7 months in the gefitinib only arm (P=0.47). The combination of ficlatuzumab with gefitinib showed a trend for improved ORR and PFS in a subgroup of patients with EGFR-sensitizing mutations and low MET biomarker levels. Preliminary results suggested improved survival with the combination in patients with high stromal HGF (P=0.03), but no difference in the overall population. Paronychia (47%), acne (27%), peripheral edema (38%), and eczema (17%) were the most common side effects associated with the combination therapy.
TAK701

TAK701 is a humanized anti-HGF monoclonal antibody that was found to overcome gefitinib resistance in EGFR-mutated human NSCLC cell lines both in vitro and in xenograft mouse models. A Phase I study with TAK701 in advanced solid malignancies revealed no specific dose-limiting toxicities, with cough, fatigue, and constipation as the common adverse events.

Anti-MET monoclonal antibodies

Onartuzumab

Onartuzumab (MetMAb) is a humanized monoclonal antibody which binds to the extracellular SEMA domain of MET. As a result, onartuzumab blocks the binding of the HGF α-chain to the MET receptor. In an orthotopic mouse xenograft model with KP4 pancreatic cancer cells, onartuzumab inhibited tumor growth, reduced MET phosphorylation with a concomitant decrease in Ki-67 index, and improved survival of the mice. A Phase I dose-escalation study evaluated single agent onartuzumab and a combination of onartuzumab plus bevacizumab in advanced solid malignancies in 43 patients. The half-life for onartuzumab was 11 days, and no adverse pharmacokinetic interactions with bevacizumab were observed. The most common treatment-related adverse events included fatigue, peripheral edema, and hypoalbuminemia. In a Phase II study of erlotinib in combination with onartuzumab in patients with advanced NSCLC after initial therapy, 69 patients were randomized to receive onartuzumab 15 mg/kg intravenously every 3 weeks in combination with erlotinib 150 mg daily, and 68 patients received placebo intravenously every 3 weeks with erlotinib 150 mg daily. In patients with positive MET immunohistochemical staining (defined as ≥50% tumor cells with moderate or strong staining intensity by immunohistochemistry [IHC]), the addition of onartuzumab to erlotinib resulted in a significant improvement in PFS from 1.5 to 2.9 months and median overall survival from 3.8 to 12.6 months. A Phase III clinical trial evaluating the combination of erlotinib with onartuzumab in NSCLC (MetLUNG study) is currently ongoing. A Phase II randomized double-blind, placebo-controlled clinical trial comparing cytotoxic chemotherapy with oxaliplatin, 5-fluouracil, and leucovorin (mFOLFOX-6) combined with bevacizumab and placebo to mFOLFOX-6 with bevacizumab and onartuzumab is also currently ongoing.

Biomarkers for MET inhibitors

In the era of targeted agents, it is critically important to identify biomarkers which predict response to a specific class of agents. Although a number of predictive biomarkers to HGF-MET inhibitors are currently being evaluated, to date none have yet been validated or FDA-approved. Potential biomarkers explored in clinical trials to predict response to HGF-MET inhibitors include MET amplification (MET/Centromere enumeration probe 7 [CEP7] ratio >2 in 200 interphase nuclei), MET translocation, MET mutations, quantitative IHC for total MET or phosphorylated MET, plasma levels of HGF, and soluble MET receptor. In preclinical studies with PHA-665752, a MET inhibitor, the investigators demonstrated that MET amplification was an excellent predictor of PHA-665752 sensitivity in 41 human NSCLC cell lines. BAY-853474, another specific MET inhibitor, was able to reduce the tumor burden in glioblastoma, NSCLC, and gastric cancer xenograft models. The inhibition of MET phosphorylation was dose-dependent, and the soluble plasma biomarkers HGF, VEGF, and interleukin-8, as well as the MET-ectodomain, could potentially be used to monitor the response to treatment. However, clinical samples showed only moderately elevated levels of these biomarkers even with MET amplification. This study supported the use and development of IHC-based analysis of MET phosphorylation in addition to plasma biomarkers for monitoring response.

Treatments with fclaruzumab and rilotumumab have been shown to result in an increase in plasma total HGF and soluble MET concentrations from baseline. Elevation of plasma total HGF and soluble MET concentrations were reported as pharmacodynamic biomarkers. In a Phase Ib/II clinical trial combining rilotumumab with panitumumab (a human monoclonal antibody to EGFR) for KRAS wild-type metastatic colorectal carcinomas, response rate to the combination correlated with high cytoplasmic staining for MET in tumor cells. Exploratory biomarker analyses performed on patients with advanced NSCLC (n=128) receiving onartuzumab in combination with erlotinib demonstrated an OS benefit in MET-positive patients (n=65), defined as ≥50% of tumor cells staining ≥2+ intensity for MET by IHC; HR =0.37, P=0.002. A subgroup analysis suggested IHC analysis of MET expression was a more sensitive predictor than MET amplification as assessed by FISH. In a multicenter Phase II randomized controlled trial, MET-expression-positive patients (defined as MET ≥2+ in >50% of tumor at IHC) with unresectable hepatocellular carcinoma showed a significant benefit with tivantinib in the second-line setting. Interestingly, another Phase II trial with tivantinib demonstrated no obvious relationship of treatment outcome with biomarkers, including MET gene amplification,
phospho-MET and HGF expression in tumor, and serum HGF. Recently, the use of gene expression profiling has allowed for the identification of specific gene signatures which can be used to classify and predict tumor responses to targeted agents or chemotherapy. Such signatures are currently being developed and tested for colorectal carcinomas. Thus, future clinical trials need to better identify and refine biomarkers, which will allow for better prediction of response to MET inhibitors.

Mechanisms of resistance to HGF-MET inhibitors

Since solid malignancies are comprised of highly heterogeneous groups of cells, the use of targeted inhibitors may select a malignant clone of cells, which are inherently resistant to blockage of the HGF-MET pathway. Acquired resistance in cancer cells can develop by point mutations, which inhibit the interaction and/or binding of a molecule to its target receptor. Another mechanism of acquired resistance is activation of compensatory signaling pathways or mechanisms, which can bypass the effects of targeted agents. In a preclinical model, exposure to MET inhibitors PHA-665752 and PF-2341066 led to MET resistance through an acquired mutation in the MET activation loop (Y1230H/C). In addition, overexpression of TGF-α, a ligand for EGFR, resulted in activation of the EGFR pathway and subsequent resistance to MET inhibitors. In a MET-amplified gastric cancer cell line GTL16, prolonged exposure to PF-04217903 resulted in 7q32-34 amplification and overexpression of a novel Staphylococcal Nuclease And Tudor Domain Containing 1-v-raf murine sarcoma viral oncogene homolog B (SND1-BRAF) fusion protein. The constitutively active SND1-BRAF fusion protein resulted in upregulation and activation of the mitogen-activated protein kinase pathway, which conferred resistance to MET inhibition. After prolonged exposure to small molecule MET inhibitors, resistant cells developed MET and KRAS amplification. KRAS amplification was associated with loss of MET dependence and resistance to MET inhibitors. A patient with MET-mutated papillary renal cell carcinoma treated with PF-04217903 was noted to have an acquired tandem duplication of the mutated MET gene and developed resistance to PF-04217903-mediated MET inhibition. Strategies to overcome HGF-MET resistance would involve targeting of multiple compensatory pathways simultaneously either by using multitargeted agents such as cabozantinib (MET, VEGF), crizotinib (MET, ALK), or by combining targeted agents like onartuzumab or flicutzumab with erlotinib/gefitinib (MET/ HGF and EGFR inhibitors respectively). The use of inhibitors of heat shock protein 90 (HSP90), a molecular chaperone to MET, and a wide range of other key cellular proteins may offer another approach to overcome resistance to MET inhibition.

Summary

The HGF-MET axis is frequently dysregulated in cancer, especially in advanced or metastatic disease. Upregulation of the HGF-MET axis can promote resistance to small molecule inhibition of several important cellular signaling pathways, including the EGFR, RAS-RAF-MEK, and Akt-mTOR pathways. A number of potential predictive biomarkers including MET amplification (MET/CEP7 ratio > 2 in 200 interphase nuclei), MET translocation, MET mutation analysis, quantitative IHC for total MET and phosphorylated MET, plasma levels of HGF, and soluble MET receptor, are currently being evaluated in clinical studies. HGF-MET inhibitors hold promise as novel molecules that can be used either as monotherapy or as part of combination therapy with EGFR, RAS-RAF-MEK, and Akt-mTOR inhibitors in the treatment of various human cancers. To conclude, in the era of personalized medicine, there is an increased need to validate biomarkers in specific tumor types to identify patients who will benefit from HGF-MET inhibitors.

Acknowledgment

This review was supported, in part, by the Phase I U01-CA099168 grant from the National Institutes of Health/National Cancer Institute.

Disclosure

L Appleman received research funding from Amgen, Bayer, and Exelixis. The authors report no other conflicts of interest in this work.

References


86. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. *J Clin Oncol*. 2011;29(Suppl; abstr 7505).


90. Eng C, Van Cutsen E, Nowara A, et al. A randomized, phase Ib/II trial of rivalumumab (AMG 102, ril) or ganitumumab (AMG 479, gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. *J Clin Oncol*. 2011;29(Suppl; abstr 3500).


